Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition
In Brief

Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition

March 06, 2026
Vol.52 No.09
The Directors: Yolanda Sanchez and Kelvin Lee talk about making cancer centers more resilient
PodcastThe Directors

The Directors: Yolanda Sanchez and Kelvin Lee talk about making cancer centers more resilient
“Diverse ecosystems are more robust than non-diverse ecosystems. That is a biological fact.”

February 27, 2026
Vol.52 No.08
By Claire Marie Porter and Paul Goldberg
The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades ago
NCI

The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades ago
Lowy: “We still have percentiles, but we’re not allowed to make awards exclusively on the basis of payline.”

February 13, 2026
Vol.52 No.06
By Jacquelyn Cobb
Team USA’s Julie Letai competes in Milan Olympics speed skating event
In Brief

Team USA’s Julie Letai competes in Milan Olympics speed skating event

February 13, 2026
Vol.52 No.06
Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
NCI

Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
The group replaced the NCI Board of Scientific Advisors

February 06, 2026
Vol.52 No.05
By Claire Marie Porter
Black History Month: Otis Brawley shares how lessons learned in West Side Detroit shape his stance on cancer prevention
Black History MonthPodcast

Black History Month: Otis Brawley shares how lessons learned in West Side Detroit shape his stance on cancer prevention
“Trying to realize how good we actually could be if our system were truly efficient is what Otis is all about”

February 06, 2026
Vol.52 No.05
By Robert A. Winn, Otis W. Brawley and Preston Willett
The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)
PodcastThe Directors

The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)
Cancer centers fund small grants to boost morale amid low paylines

January 30, 2026
Vol.52 No.04
By Paul Goldberg and Claire Marie Porter
FY26 funding package blocked in Senate after ICE shooting of Alex Pretti
Capitol Hill

FY26 funding package blocked in Senate after ICE shooting of Alex Pretti
New package—likely excluding DHS—may go back to House early next week

January 30, 2026
Vol.52 No.04
By Jacquelyn Cobb
Bernie Lewinsky’s collection of artifacts captures “the learning curve” of radiation oncology
FreeIn the Archives

Bernie Lewinsky’s collection of artifacts captures “the learning curve” of radiation oncology

January 23, 2026
Vol.52 No.03
By Sara Willa Ernst
With streamlined, “sitevisitless” CCSG review in place, cancer centers remained stable in 2025
Guest Editorial

With streamlined, “sitevisitless” CCSG review in place, cancer centers remained stable in 2025

December 19, 2025
Vol.51 No.46
By Richard J. Jones

Posts navigation

12…37Next

Trending Stories

  • Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
  • Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
  • Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)
  • One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
  • As more people are surviving cancer, we must continue funding bold science
  • GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
    Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account